These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 7846824)

  • 1. Enrofloxacin treatment of gram-negative infections.
    Rutgers HC; Stepien RL; Elwood CM; Simpson KW; Batt RM
    Vet Rec; 1994 Oct; 135(15):357-9. PubMed ID: 7846824
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats.
    Boothe DM; Boeckh A; Simpson RB; Dubose K
    J Vet Intern Med; 2006; 20(6):1297-306. PubMed ID: 17186841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antimicrobial activity of marbofloxacin and enrofloxacin against bacterial strains isolated from companion animals.
    Farca AM; Cavana P; Robino P; Nebbia P
    Schweiz Arch Tierheilkd; 2007 Jun; 149(6):265-71. PubMed ID: 17645036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial prostatitis in a cat.
    Roura X; Camps-Palau MA; Lloret A; García F; Espada I
    J Vet Intern Med; 2002; 16(5):593-7. PubMed ID: 12322712
    [No Abstract]   [Full Text] [Related]  

  • 5. Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections.
    Cooke CL; Singer RS; Jang SS; Hirsh DC
    J Am Vet Med Assoc; 2002 Jan; 220(2):190-2. PubMed ID: 12126128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones.
    Gottlieb S; Wigney DI; Martin PA; Norris JM; Malik R; Govendir M
    Aust Vet J; 2008 Apr; 86(4):147-52. PubMed ID: 18363989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiating effect of EDTA-Tris on the activity of antibiotics against resistant bacteria associated with otitis, dermatitis and cystitis.
    Farca AM; Piromalli G; Maffei F; Re G
    J Small Anim Pract; 1997 Jun; 38(6):243-5. PubMed ID: 9200113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Questions study on Escherichia coli susceptibility.
    Goering RV
    J Am Vet Med Assoc; 2002 Apr; 220(8):1139; author reply 1139-41. PubMed ID: 11990957
    [No Abstract]   [Full Text] [Related]  

  • 9. What is your diagnosis?. Infected fracture with secondary osteomyelitis.
    Ferguson JF
    J Small Anim Pract; 1995 Aug; 36(8):348, 373-4. PubMed ID: 8558865
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of enrofloxacin.
    Dick GC
    Vet Rec; 1993 Jun; 132(24):616. PubMed ID: 8393228
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
    Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
    Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic susceptibility of bacteria isolated from infections in cats and dogs throughout Europe (2002-2009).
    Kroemer S; El Garch F; Galland D; Petit JL; Woehrle F; Boulouis HJ
    Comp Immunol Microbiol Infect Dis; 2014 Mar; 37(2):97-108. PubMed ID: 24447508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of Pseudomonas isolates from the ears and skin of dogs to enrofloxacin, marbofloxacin, and ciprofloxacin.
    Wildermuth BE; Griffin CE; Rosenkrantz WS; Boord MJ
    J Am Anim Hosp Assoc; 2007; 43(6):337-41. PubMed ID: 17975216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and mechanisms of resistance to fluoroquinolones in Pseudomonas aeruginosa and Escherichia coli isolates recovered from dogs suffering from otitis in Greece.
    Vingopoulou EI; Delis GA; Batzias GC; Kaltsogianni F; Koutinas A; Kristo I; Pournaras S; Saridomichelakis MN; Siarkou VI
    Vet Microbiol; 2018 Jan; 213():102-107. PubMed ID: 29291992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of enrofloxacin for the treatment of experimentally induced Ehrlichia canis infection.
    Neer TM; Eddlestone SM; Gaunt SD; Corstvet RE
    J Vet Intern Med; 1999; 13(5):501-4. PubMed ID: 10499737
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of fluoroquinolones for companion animal antimicrobial therapy.
    Walker RD
    Aust Vet J; 2000 Feb; 78(2):84-90. PubMed ID: 10736664
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of resistant bacteria isolated from dogs with otitis externa or urinary tract infections after exposure to enrofloxacin in vitro.
    Brothers AM; Gibbs PS; Wooley RE
    Vet Ther; 2002; 3(4):493-500. PubMed ID: 12584687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of enrofloxacin or doxycycline for treatment of Bartonella henselae or Bartonella clarridgeiae infection in cats.
    Kordick DL; Papich MG; Breitschwerdt EB
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2448-55. PubMed ID: 9371348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activity of enrofloxacin against Staphylococcus intermedius strains isolated from canine pyodermas.
    Ganière JP; Médaille C; Limet A; Ruvoen N; André-Fontaine G
    Vet Dermatol; 2001 Jun; 12(3):171-5. PubMed ID: 11420933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro potency and efficacy favor later generation fluoroquinolones for treatment of canine and feline Escherichia coli uropathogens in the United States.
    Liu X; Boothe DM; Jin Y; Thungrat K
    World J Microbiol Biotechnol; 2013 Feb; 29(2):347-54. PubMed ID: 23136054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.